Is tranexamic acid toxic to articular cartilage when administered topically?

Bone and Joint Journal

Volumn 100B, Issue 3, 2018, Pages 404-412

  Parker, J D ^a   Lim, K S ^a   Kieser, D C ^a   Woodfield, T B F ^a   Hooper, G J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

ARTICLE; ARTICULAR CARTILAGE; CELL ADHESION; CELL METABOLISM; CELL PROTECTION; CELL STRUCTURE; CELL VIABILITY; CHONDROCYTE; CLINICAL PRACTICE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EXPOSURE; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION; APOPTOSIS; CELL CULTURE; DRUG EFFECTS; KNEE REPLACEMENT; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION; ANTIFIBRINOLYTIC AGENTS; APOPTOSIS; ARTHROPLASTY, REPLACEMENT, KNEE; CARTILAGE, ARTICULAR; CELL ADHESION; CELLS, CULTURED; CHONDROCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; TRANEXAMIC ACID;

EID: 85044691356     PISSN: 20494394     EISSN: 20494408     Source Type: Journal    
DOI: 10.1302/0301-620X.100B3.BJJ-2017-1135.R1     Document Type: Article

References (31)

1. No authors listed. Tranexamic Acid. DrugBank. https://www.drugbank.ca/drugs/ DB00302 Published 2016 (date last accessed 14 December 2017).
2. Nilsson IM. Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl (R Coll Pathol) 1980;14(Suppl):41-47.
3. Watts G. Utako Okamoto. Lancet 2016;387:2286.
4. No authors listed. WHO Model List of Essential Medicines, 19th List (April 2015). World Health Organization. http://www.who.int/medicines/publications/essentialmedicines/ EML-2015-FINAL-amended-NOV2015.pdf?.ua=1 (date last accessed 14 December 2017).
5. British Medical Assocation, Royal Pharmaceutical Society of Great Britain. BNF 69 (British National Formulary). 69th ed. London: Pharmaceutical Press, 2015. http://www.worldcat.org/title/british-national-formulary-bnf-69-september-2014-march-2015/oclc/905488864?.ht=edition&referer=br (date last accessed 14 December 2017).
6. Shakur H, Roberts I, Fawole B, et al. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): An international, randomised, double-blind, placebo-controlled trial. Lancet 2017;389:2105-2116.
7. Maniar RN, Kumar G, Singhi T, Nayak RM, Maniar PR. Most effective regimen of tranexamic acid in knee arthroplasty: A prospective randomized controlled study in 240 patients. Clin Orthop Relat Res 2012;470:2605-2612.
8. Xie J, Hu Q, Ma J, Huang Q, Pei F. Multiple boluses of intravenous tranexamic acid to reduce hidden blood loss and the inflammatory response following enhancedrecovery primary total hip arthroplasty: A randomised clinical trial. Bone Joint J 2017;99-B:1442-1449.
9. Sassoon A, Nam D, Jackups R, et al. Tranexamic acid: Optimal blood loss management in surface replacement arthroplasty. Bone Joint J 2016;98-B:173-178.
10. Karaaslan F, Karao?.lu S, Yurdakul E. Reducing intra-articular hemarthrosis after arthroscopic anterior cruciate ligament reconstruction by the administration of intravenous tranexamic acid: A prospective, randomized controlled trial. Am J Sports Med 2015;43:2720-2726.
11. Mao Z, Yue B, Wang Y, Yan M, Dai K. A comparative, retrospective study of peri-articular and intra-articular injection of tranexamic acid for the management of postoperative blood loss after total knee arthroplasty. BMC Musculoskelet Disord 2016;17:438.
12. Yuan ZF, Yin H, Ma WP, Xing DL. The combined effect of administration of intravenous and topical tranexamic acid on blood loss and transfusion rate in total knee arthroplasty: Combined tranexamic acid for TKA. Bone Joint Res 2016;5:353-361.
13. Morrison RJM, Tsang B, Fishley W, et al. Dose optimisation of intravenous tranexamic acid for elective hip and knee arthroplasty. Bone Joint Res 2017;6:499-505.
14. Tuttle JR, Feltman PR, Ritterman SA, Ehrlich MG. Effects of Tranexamic Acid Cytotoxicity on In Vitro Chondrocytes. Am J Orthop (Belle Mead NJ) 2015;44:E497-E502.
15. Ahlberg A, Eriksson O, Kjellman H. Diffusion of tranexamic acid to the joint. Acta Orthop Scand 1976;47:486-488.
16. Cox S, Cole M, Mankarious S, Tawil N. Effect of tranexamic acid incorporated in fibrin sealant clots on the cell behavior of neuronal and nonneuronal cells. J Neurosci Res 2003;72:734-746.
17. Furst W, Banerjee A, Redl H. Comparison of structure, strength and cytocompatibility of a fibrin matrix supplemented either with tranexamic acid or aprotinin. J Biomed Mater Res Part B Appl Biomater 2007;82-B:109-114.
18. Sa-Ngasoongsong P, Chanplakorn P, Wongsak S, et al. An in vivo study of lowdose intra-articular tranexamic acid application with prolonged clamping drain method in total knee replacement: Clinical efficacy and safety. Biomed Res Int 2015;2015:164206.
19. Seo J- G, Moon Y- W, Park S- H, Kim S- M, Ko K- R. The comparative efficacies of intra-articular and IV tranexamic acid for reducing blood loss during total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc 2013;21:1869-1874.
20. Tzatzairis TK, Drosos GI, Kotsios SE, et al. Intravenous vs topical tranexamic acid in total knee arthroplasty without tourniquet application: A randomized controlled study. J Arthroplasty 2016;31:2465-2470.
21. Zhang Y, Zhang L, Ma X, et al. What is the optimal approach for tranexamic acid application in patients with unilateral total hip arthroplasty?. Orthopade 2016;45:616-621.
22. Pauzenberger L, Domej MA, Heuberer PR, et al. The effect of intravenous tranexamic acid on blood loss and early post-operative pain in total shoulder arthroplasty. Bone Joint J 2017;99-B:1073-1079.
23. Lim KS, Schon BS, Mekhileri NV, et al. New visible-light photoinitiating system for improved print fidelity in gelatin-based bioinks. ACS Biomater Sci Eng 2016;2:1752-1762.
24. Jennings JD, Solarz MK, Haydel C. Application of tranexamic acid in trauma and orthopedic surgery. Orthop Clin North Am 2016;47:137-143.
25. Lin C, Qi Y, Jie L, et al. Is combined topical with intravenous tranexamic acid superior than topical, intravenous tranexamic acid alone and control groups for blood loss controlling after total knee arthroplasty: A meta-analysis. Medicine (Baltimore) 2016;95:5344.
26. Shang J, Wang H, Zheng B, Rui M, Wang Y. Combined intravenous and topical tranexamic acid versus intravenous use alone in primary total knee and hip arthroplasty: A meta-analysis of randomized controlled trials. Int J Surg 2016;36(Pt A):324-329.
27. Sitek P, Wysocka-Wycisk A, Kpski F, et al. PRP-fibrinogen gel-like chondrocyte carrier stabilized by TXA-preliminary study. Cell Tissue Bank 2013;14:133-140.
28. Levett PA, Melchels FPW, Schrobback K, et al. A biomimetic extracellular matrix for cartilage tissue engineering centered on photocurable gelatin, hyaluronic acid and chondroitin sulfate. Acta Biomater 2014;10:214-223.
29. Schuurman W, Levett PA, Pot MW, et al. Gelatin-methacrylamide hydrogels as potential biomaterials for fabrication of tissue-engineered cartilage constructs. Macromol Biosci 2013;13:551-561.
30. Aggarwal AK, Singh N, Sudesh P. Topical vs intravenous tranexamic acid in reducing blood loss after bilateral total knee arthroplasty: A prospective study. J Arthroplasty 2016;31:1442-1448.
31. Liu M, Zeng X, Ma C, et al. Injectable hydrogels for cartilage and bone tissue engineering. Bone Res 2017;5:17014.